Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 4Neoplasms 3Small Cell Lung Carcinoma 2Recurrence 2Lymphoma 2Non-Erosive Reflux Disease 1Melanoma 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Hematologic Neoplasms 1Gastrointestinal Hemorrhage 1Gastroesophageal Reflux 1Dyspepsia 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1Barrett Esophagus 1Atrophy 1Advanced Solid Tumors 1Advanced Solid Malignancies 1Adenocarcinoma 1Acrocephalosyndactylia 1

Interventions

pemigatinib 6infigratinib 3erdafitinib 2derazantinib 2Rogaratinib 2pembrolizumab 1lenvatinib 1exemestane 1brivanib 1atezolizumab 1Rabeprazole 1Irinotecan 1INCB 54828-101 1Gemcitabine 1Fulvestrant 1E-3810 1Drug Combinations 1Carboplatin 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Acrocephalosyndactylia × Rabeprazole × Clear all
NCT02747797 2018-08-02

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

University of California, San Diego

Phase 2 Withdrawn

Acrocephalosyndactylia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡